This page has only limited features, please log in for full access.

Unclaimed
Louise Redder
Quality of Life Research Center, Department of Haematology, Odense University Hospital, 5000 Odense C, Denmark

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 27 August 2021 in COVID
Reads 0
Downloads 0

In general, governments and health authorities have taken precautions during the COVID-19 pandemic to reduce the viral spread and protect vulnerable citizens. Patients with multiple myeloma (MM) have an increased risk of being infected with COVID-19 and developing a fatal course due to the related immunodeficiency. We investigated how Danish patients with MM reported their quality of life (QoL) pre-COVID and during COVID, in an ongoing longitudinal QoL survey. The responses given during the first and second wave of the COVID-19 pandemic were pooled, analyzed and compared to the same period the year before. We hypothesized that locking down the society would have caused deteriorated QoL and that patients living alone and those under the age of 65 would be particularly affected by the situation. Surprisingly, our study showed the opposite. Statistically significant and clinically relevant differences were primarily found during the first lock down and represented reduced fatigue, improved role functioning, decreased insomnia and improved physical health summaries in patients below 65 years of age. These results indicate that Danish patients with MM might have felt protected and safe by COVID restrictions. Otherwise, the questionaries used in QoL-MM survey may not have been able to capture the impact of the COVID-19 pandemic. Importantly, this indicates that QoL survey data obtained in clinical studies, in countries with highly developed health-care systems using standard questionnaires during the pandemic, allow room for interpretation without being adjusted for the impacts of the pandemic.

ACS Style

Louise Redder; Sören Möller; Anna Thit Johnsen; Mary Jarden; Christen Lykkegaard Andersen; Bo Amdi Jensen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard; Lene Kongsgaard Nielsen. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. COVID 2021, 1, 303 -314.

AMA Style

Louise Redder, Sören Möller, Anna Thit Johnsen, Mary Jarden, Christen Lykkegaard Andersen, Bo Amdi Jensen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Saaby Steffensen, Per Trøllund Pedersen, Maja Hinge, Mikael Frederiksen, Carsten Helleberg, Anne Kærsgaard Mylin, Niels Abildgaard, Lene Kongsgaard Nielsen. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. COVID. 2021; 1 (1):303-314.

Chicago/Turabian Style

Louise Redder; Sören Möller; Anna Thit Johnsen; Mary Jarden; Christen Lykkegaard Andersen; Bo Amdi Jensen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard; Lene Kongsgaard Nielsen. 2021. "Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic." COVID 1, no. 1: 303-314.

Short report
Published: 09 June 2020 in British Journal of Haematology
Reads 0
Downloads 0

In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a population‐based setting we performed a study of the entire cohort of transplant ineligible MM patients above 65 years in the Danish National MM Registry. Our data confirmed the value of the MRP. In a cohort of 1,377 patients, the MRP score separated patients into three distinct risk‐groups with an observed hazard ratio of 2.91 for early death in high‐risk versus low‐risk patients.

ACS Style

Louise Redder; Tobias W. Klausen; Annette Juul Vangsted; Henrik Gregersen; Niels F. Andersen; Robert S. Pedersen; Agoston G. Szabo; Mikael Frederiksen; Ulf C. Frølund; Carsten Helleberg; Lene Kongsgaard Nielsen; Per T. Pedersen; Morten Salomo; Peter Gimsing; Henrik Frederiksen; Niels Abildgaard. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry. British Journal of Haematology 2020, 193, 119 -124.

AMA Style

Louise Redder, Tobias W. Klausen, Annette Juul Vangsted, Henrik Gregersen, Niels F. Andersen, Robert S. Pedersen, Agoston G. Szabo, Mikael Frederiksen, Ulf C. Frølund, Carsten Helleberg, Lene Kongsgaard Nielsen, Per T. Pedersen, Morten Salomo, Peter Gimsing, Henrik Frederiksen, Niels Abildgaard. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry. British Journal of Haematology. 2020; 193 (1):119-124.

Chicago/Turabian Style

Louise Redder; Tobias W. Klausen; Annette Juul Vangsted; Henrik Gregersen; Niels F. Andersen; Robert S. Pedersen; Agoston G. Szabo; Mikael Frederiksen; Ulf C. Frølund; Carsten Helleberg; Lene Kongsgaard Nielsen; Per T. Pedersen; Morten Salomo; Peter Gimsing; Henrik Frederiksen; Niels Abildgaard. 2020. "Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry." British Journal of Haematology 193, no. 1: 119-124.